Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4 - Wikidata - wikimedia - TriplyDB

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

http://www.wikidata.org/entity/Q36488714

about

Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibit Overcoming therapeutic resistance in glioblastoma: the way forward Interleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response.Identification of a novel small molecule HIF-1alpha translation inhibitor.Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo Hypoxia enhances the replication of oncolytic herpes simplex virus Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus Integrated transcriptomic response to cardiac chronic hypoxia: translation regulators and response to stress in cell survival.Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.Molecular-genetic imaging of cancer.Gene expression and hypoxia in breast cancer.Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.Oncolytic virotherapy as a personalized cancer vaccine.Gene therapy approaches to enhance bioreductive drug treatment.Advances in oncolytic virus therapy for glioma.Armed replicating adenoviruses for cancer virotherapy.Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.New perspectives in cancer virotherapy: bringing the immune system into play.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Oncolytic viruses: a new class of immunotherapy drugs.Oncolytic Immunotherapy for Treatment of Cancer.Oncolytic viruses-immunotherapeutics on the rise.Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.Oncolytic viruses from the perspective of the immune system.Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.

P2860

Q26738338-5196FE8F-A281-4BAF-9B57-1923FDDB138C Q28833679-A67AB002-DC67-418E-8B76-13BB8B8DD1D3 Q29248396-8653457A-6B71-434E-9F6E-F7B7F90D87B2 Q30802553-3FE76CF9-C521-4BD1-943F-7CECB0A48E5F Q33507488-4C6A6581-A21F-460E-8DF8-9D41C92C7371 Q33622711-1F091FAD-EE86-43C3-93FB-05A4C44B224F Q33638956-865AE340-B0A7-48E3-B93D-9C1C535F446A Q33660631-2E2517C4-C391-4308-B536-717FB706DBAE Q33690982-9FD68229-6EC2-4A8C-AF54-86996C8AA389 Q33799336-4367D32F-9FD1-482F-9E5B-F484AB05462D Q33989679-160ED547-839D-496E-A883-4E983FB481F5 Q34055865-108A0F99-9173-490F-9542-0B7CB98C9852 Q35116121-2EA3492E-9A4B-40CC-9EE7-8E661BE56EF9 Q35614451-C8CE1EE1-9ECE-4B9F-961C-101FC38E700E Q35799673-81030501-0482-4BCA-B70A-B635235B5B12 Q35967008-301AE768-5AB2-4CE9-8091-5B1FC51EAC05 Q36634430-B038E7BE-D50A-4D49-BCB6-3DE2F91D7C5E Q37130170-ED1D09AD-E5E9-4CC6-8E34-1142235A9C9C Q37171980-A4821B3D-648E-4F08-9363-693C3CB9425B Q37280249-E3A04520-3D58-403D-B699-828F9FFF9BF0 Q37287118-52138941-C815-4030-937B-B94AADAD9B24 Q37386616-1FDDF462-BE1C-4684-BDC9-5577A0E7C2F6 Q37442235-4F39A2FE-F0B1-45FE-BC7D-605DFF3C87FC Q37622288-7D47241B-5DFE-4B53-96FA-A511BE293683 Q37733550-ED996A82-F882-4341-97BD-02511F3184AC Q37773253-4441E1D7-179D-407E-88A6-BC0C3D10182A Q38073096-D82F2212-7E5E-427C-B57B-EDA611693577 Q38097867-86537ED9-56EC-4840-8245-CF81418B89D3 Q38223419-7C5D19B2-D425-41F2-A57B-F6755CE39CAD Q38577450-EC50E7AC-5A85-4734-9742-72FD58E89EBA Q38848223-4DAA8EB2-0068-4407-A98E-9C54436DFD60 Q38919107-315C65E6-EB1D-4357-9777-BFD3B292C66A Q39290679-AEBA4D6A-0C67-4BA1-A568-477ABD1B86B5 Q39437927-8655701C-C0E1-4F17-B179-34B72E905033 Q39491365-5AF4AC4D-4309-46B2-AA85-D6E13A11A52C Q39573234-0B1E604F-93C4-45D3-BBA0-F5A72A4BE022 Q39646942-7B6CD574-2CCF-41E6-AFC0-680F98C5A897 Q39974038-8848835D-95CD-4960-A1AD-9B0ADCC4042E Q41684403-B2EA2AE6-DFE7-40D0-AAF1-1A7B27C6A0EE Q42084870-D8169D0D-5A51-4F7B-83AD-66242728C851

P2860

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

http://www.wikidata.org/entity/Q36488714

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@ast

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@en

type

label

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@ast

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@en

prefLabel

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@ast

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@en

P1433

Q36488714-93221336-83F1-4CD7-AD54-6D5DA349F73C

P1476

Q36488714-99C12DDE-CE3C-4B12-84A8-F7F2888003B0

P2093

Q36488714-0B2BF1C1-9BF5-48D8-A0F1-4017783F5D77

Q36488714-19B2947D-B528-4F5F-BE26-614C5057E513

Q36488714-35A189AD-927E-46B1-8AB3-F114E272A324

Q36488714-5A6A6925-7540-474D-A1FC-9EB930BCAF75

Q36488714-6EE66305-F495-4105-A65A-49AB67C3D94B

Q36488714-9606C07D-D237-4155-9073-1E38186412DC

Q36488714-DBC6D0F2-6985-401F-B122-52CC4ECF4F35

P2860

Q36488714-08DDFE4C-AB59-41BB-94EF-B8B0319C405C

Q36488714-0E549592-F028-43E2-B5F6-154BE32CEABA

Q36488714-18809692-1259-4B6A-9073-C10F925C2E8B

Q36488714-1899AE1C-72FC-444A-903F-46B73F3630A1

Q36488714-1B2089A3-35BF-4CA4-90B4-CA96D24DEB41

Q36488714-23902024-D52E-4483-B3DC-C34D67FA326D

Q36488714-28545178-5252-4FB8-A761-61931CB0DBC1

Q36488714-291F1F59-6B47-4143-A4B5-C4C0B502C4B0

Q36488714-313F9305-0DB5-4F35-860B-047984703D54

Q36488714-342D098E-DA3F-4793-9662-CC5109FEDF84

P304

Q36488714-9DB868EE-E7DD-47BF-BF58-2F96B81B35EB

P31

Q36488714-5DB82FD4-F2CD-4885-8103-93C0CC1B1A4F

P356

Q36488714-2A6DA283-357C-4EDB-A7C4-EB50FD727F84

P407

Q36488714-E7B705D1-E8E2-4759-BF8F-44A44436B3DC

P433

Q36488714-09DADDAB-D05D-492E-BA89-D2D24923BDE1

P478

Q36488714-C7AF2571-7AE4-4583-911E-9F06A21CB75C

P50

Q36488714-F51B3811-D26C-448F-9639-262F6EBAD78F

P577

Q36488714-B1E41FB3-F3FE-4626-B5FC-E51DFCB5C24E

P5875

Q36488714-9754D9B1-2496-4333-953D-BB724C50E3CA

P698

Q36488714-E149E1B9-438F-4371-AB36-D9CC8D1A9CA5

P921

Q36488714-39A38FEA-EE61-4498-8DF3-28290A799AF8

Q36488714-8285EFC0-BA10-4739-8335-0D4738ABB54C

Q36488714-BEAD5680-0C4F-4653-AD9C-C0FD8E8242E5

Q36488714-E01C788E-677C-4AC7-9155-8DE5C55CA73D

Q36488714-cc8a258b-7ecd-4363-a9e3-9857e6f64056

P932

Q36488714-B3F06BB8-9C4A-47AF-A95A-AE10F88CA08B

P356

0008-5472.CAN-06-3244

P1433

Cancer Research

P1476

Targeted cancer gene therapy u ...... virus armed with interleukin-4

@en

P2093

Daniel J Brat

http://www.w3.org/2001/XMLSchema#string

Dawn E Post

http://www.w3.org/2001/XMLSchema#string

Eric M Sandberg

http://www.w3.org/2001/XMLSchema#string

Michele M Kyle

http://www.w3.org/2001/XMLSchema#string

Mourad Tighiouart

http://www.w3.org/2001/XMLSchema#string

Narra Sarojini Devi

http://www.w3.org/2001/XMLSchema#string

Zhiheng Xu

http://www.w3.org/2001/XMLSchema#string

P2860

A simplified system for generating recombinant adenoviruses

Targeting HIF-1 for cancer therapy

Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

Hypoxia inducible factor-1alpha as a cancer drug target

Exploiting tumour hypoxia in cancer treatment

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

P304

6872-6881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-06-3244

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Erwin G Van Meir

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6199479

http://www.w3.org/2001/XMLSchema#string

P698

17638898

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2262867

http://www.w3.org/2001/XMLSchema#string